An update on photodynamic therapy in age-related macular degeneration

Ehud Rechtman, Thomas A. Ciulla, Mark H. Criswell, Ayala Pollack, Alon Harris

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

Original languageEnglish
Pages (from-to)931-938
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number7
DOIs
StatePublished - 2002

Fingerprint

Photochemotherapy
Macular Degeneration
Western World
Light Coagulation
Cost-Benefit Analysis
Epidemiology
Lasers
Drug Therapy
Therapeutics
Research
verteporfin

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularisation
  • Eye
  • Photodynamic therapy
  • Verteporfin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

An update on photodynamic therapy in age-related macular degeneration. / Rechtman, Ehud; Ciulla, Thomas A.; Criswell, Mark H.; Pollack, Ayala; Harris, Alon.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 7, 2002, p. 931-938.

Research output: Contribution to journalArticle

Rechtman, Ehud ; Ciulla, Thomas A. ; Criswell, Mark H. ; Pollack, Ayala ; Harris, Alon. / An update on photodynamic therapy in age-related macular degeneration. In: Expert Opinion on Pharmacotherapy. 2002 ; Vol. 3, No. 7. pp. 931-938.
@article{884dbc41097c47dab50bd60a8966f73c,
title = "An update on photodynamic therapy in age-related macular degeneration",
abstract = "Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15{\%} of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30{\%} of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.",
keywords = "Age-related macular degeneration, Choroidal neovascularisation, Eye, Photodynamic therapy, Verteporfin",
author = "Ehud Rechtman and Ciulla, {Thomas A.} and Criswell, {Mark H.} and Ayala Pollack and Alon Harris",
year = "2002",
doi = "10.1517/14656566.3.7.931",
language = "English",
volume = "3",
pages = "931--938",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - An update on photodynamic therapy in age-related macular degeneration

AU - Rechtman, Ehud

AU - Ciulla, Thomas A.

AU - Criswell, Mark H.

AU - Pollack, Ayala

AU - Harris, Alon

PY - 2002

Y1 - 2002

N2 - Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

AB - Age-related macular degeneration (AMD) is the leading cause of irreversible loss of central vision in people aged > 50 years in the western world. Until recently, the only proven treatment to reduce the risk of vision loss from its more severe neovascular form was laser photocoagulation, but this treatment was suitable for only 15% of cases. Photodynamic therapy (PDT) with verteporfin was recently proposed to be effective in reducing the risk of visual loss for an estimated 20 - 30% of neovascular AMD patients. This review covers AMD epidemiology, the mechanism of PDT, the 2-year results of the two major clinical studies of PDT with verteporfin, the cost-effectiveness of PDT and the current research status of other drugs for PDT in AMD.

KW - Age-related macular degeneration

KW - Choroidal neovascularisation

KW - Eye

KW - Photodynamic therapy

KW - Verteporfin

UR - http://www.scopus.com/inward/record.url?scp=0035987591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035987591&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.7.931

DO - 10.1517/14656566.3.7.931

M3 - Article

VL - 3

SP - 931

EP - 938

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -